JP2017536362A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536362A5 JP2017536362A5 JP2017526671A JP2017526671A JP2017536362A5 JP 2017536362 A5 JP2017536362 A5 JP 2017536362A5 JP 2017526671 A JP2017526671 A JP 2017526671A JP 2017526671 A JP2017526671 A JP 2017526671A JP 2017536362 A5 JP2017536362 A5 JP 2017536362A5
- Authority
- JP
- Japan
- Prior art keywords
- dihydro
- benzo
- alkyl
- nhc
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 benzo [d] isoxazolyl Chemical group 0.000 claims 75
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims 4
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 208000033679 diabetic kidney disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 claims 2
- 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 206010020571 Hyperaldosteronism Diseases 0.000 claims 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 2
- 206010021263 IgA nephropathy Diseases 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 206010061989 glomerulosclerosis Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000016998 Conn syndrome Diseases 0.000 claims 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- 208000008253 Systolic Heart Failure Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004540 benzothiazol-5-yl group Chemical group S1C=NC2=C1C=CC(=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000003585 oxepinyl group Chemical group 0.000 claims 1
- 208000013846 primary aldosteronism Diseases 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086218P | 2014-12-02 | 2014-12-02 | |
| US62/086,218 | 2014-12-02 | ||
| PCT/US2015/063064 WO2016089800A1 (en) | 2014-12-02 | 2015-12-01 | Aldosterone synthase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536362A JP2017536362A (ja) | 2017-12-07 |
| JP2017536362A5 true JP2017536362A5 (https=) | 2019-01-17 |
| JP6707084B2 JP6707084B2 (ja) | 2020-06-10 |
Family
ID=54937372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526671A Active JP6707084B2 (ja) | 2014-12-02 | 2015-12-01 | アルドステロンシンターゼ阻害薬 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9890171B2 (https=) |
| EP (1) | EP3227300B1 (https=) |
| JP (1) | JP6707084B2 (https=) |
| WO (1) | WO2016089800A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110270295B (zh) * | 2019-07-31 | 2021-08-24 | 北京六合宁远科技有限公司 | 一种氨基取代苯并吡啶含氮杂环的制备方法 |
| CN120187713A (zh) * | 2022-11-23 | 2025-06-20 | 上海翰森生物医药科技有限公司 | 吡啶多环类化合物抑制剂、及其制备方法和应用 |
| WO2024235165A1 (zh) * | 2023-05-12 | 2024-11-21 | 南京明德新药研发有限公司 | 含氮杂环类化合物及其应用 |
| CN121586708A (zh) * | 2023-07-21 | 2026-02-27 | 上海翰森生物医药科技有限公司 | 三并环类化合物、及其制备方法和应用 |
| WO2025098465A1 (zh) * | 2023-11-10 | 2025-05-15 | 上海齐鲁制药研究中心有限公司 | 稠环衍生物、其制备方法及其在医药上的应用 |
| CN121135736A (zh) * | 2024-03-01 | 2025-12-16 | 浙江扬厉医药技术有限公司 | 吡喃并吡啶类化合物、其制备方法、药物组合物及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006138714A2 (en) * | 2005-06-17 | 2006-12-28 | Janssen Pharmaceutica N.V. | Naphthyridine compounds |
| US8519134B2 (en) * | 2009-11-17 | 2013-08-27 | Novartis Ag | Aryl-pyridine derivatives as aldosterone synthase inhibitors |
| US9353081B2 (en) | 2011-09-23 | 2016-05-31 | Hoffmann-La Roche Inc. | Bicyclic dihydroquinoline-2-one derivatives |
| BR112014013136B1 (pt) * | 2011-11-30 | 2020-05-26 | F. Hoffmann-La Roche Ag | Novos derivados de dihidroisoquinolina-1-ona biciclicos |
| LT2838883T (lt) * | 2012-04-17 | 2018-01-25 | F. Hoffmann-La Roche Ag | Nauji feniltetrahidroizochinolino dariniai |
| WO2014179186A1 (en) * | 2013-04-30 | 2014-11-06 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors |
| MX2016003926A (es) * | 2013-10-17 | 2016-06-17 | Hoffmann La Roche | Nuevos derivados de fenil-dihidropiridina como inhibidores de aldosterona sintasa. |
| TWI600658B (zh) * | 2014-07-24 | 2017-10-01 | 百靈佳殷格翰國際股份有限公司 | 醛固酮合成酶抑制劑 |
| AP2017009829A0 (en) * | 2014-10-15 | 2017-03-31 | Boehringer Ingelheim Int | Aldosterone synthase inhibitors |
-
2015
- 2015-12-01 WO PCT/US2015/063064 patent/WO2016089800A1/en not_active Ceased
- 2015-12-01 JP JP2017526671A patent/JP6707084B2/ja active Active
- 2015-12-01 US US15/532,126 patent/US9890171B2/en active Active
- 2015-12-01 EP EP15813641.6A patent/EP3227300B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536362A5 (https=) | ||
| EP3820860B1 (en) | Pyridazine compounds for inhibiting nav1.8 | |
| CN107406438B (zh) | 溴结构域的抑制剂 | |
| JP6517976B2 (ja) | 炎症性障害の治療のための化合物及びその医薬組成物 | |
| CA2915622C (en) | Novel substituted bicyclic compounds as bromodomain inhibitors | |
| KR102427777B1 (ko) | 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법 | |
| WO2015015318A2 (en) | Novel quinazolinones as bromodomain inhibitors | |
| JP2013518902A5 (https=) | ||
| JP2014526500A5 (https=) | ||
| KR20150138858A (ko) | 림프종 치료를 위한 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도 | |
| JP2015536973A (ja) | ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物 | |
| US9890171B2 (en) | Aldosterone synthase inhibitors | |
| RU2015141360A (ru) | Ингибиторы тирозинкиназы брутона | |
| JP2018503647A5 (https=) | ||
| Van Der Aar et al. | Favorable human safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor GLPG1690, a potential new treatment in idiopathic pulmonary fibrosis | |
| JP2017534652A5 (https=) | ||
| HK1251553A1 (zh) | 苯并异恶唑衍生物盐 | |
| JP2015522537A5 (https=) | ||
| CZ2004524A3 (cs) | Agonisté nikotinového acetylcholinového receptoru v léčbě syndromu neklidných nohou | |
| JP2016505628A5 (https=) | ||
| JP6586326B2 (ja) | 進行前立腺癌治療薬 | |
| HK40048208A (en) | Pyridazine compounds for inhibiting nav1.8 | |
| HK40048208B (en) | Pyridazine compounds for inhibiting nav1.8 | |
| CN1201390A (zh) | 用于治疗运动障碍的5－ht3受体拮抗剂 | |
| HK1231483B (en) | Benzisoxazole derivative salt |